or Try an Advanced Search...

    Technical Analysis for ALVR - AlloVir, Inc.

    Grade Last Price % Change Price Change
    D 0.78 -1.82% -0.01
    ALVR closed down 1.82 percent on Wednesday, May 8, 2024, on 61 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical ALVR trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    20 DMA Support Bullish 0.00%
    Outside Day Range Expansion 0.00%
    NR7 Range Contraction -1.82%
    Narrow Range Bar Range Contraction -1.82%
    Inside Day Range Contraction -1.82%
    Gapped Down Weakness -1.82%
    Pocket Pivot Bullish Swing Setup -3.05%
    Overbought Stochastic Strength -3.05%
    Gapped Down Weakness -3.05%
    Older End-of-Day Signals for ALVR ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 14 hours ago
    Outside Day about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Down 2 % about 15 hours ago
    Down 1% about 15 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ALVR Chart by TradingView
    Basic chart:

    Profile

    AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Stem Cell Cell Therapy Cell Biology Gene Therapy Manufacturing Process Viruses Virus Viral Disease Immunity Covid 19 Zoonoses

    Is ALVR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 29 Are Medical Stocks Lagging AlloVir (ALVR) This Year?
    Jan 16 Top 4 Health Care Stocks That May Rocket Higher In Q1
    Dec 26 Karuna downgraded, Arm target raised: Wall Street's top analyst calls
    Dec 22 Dow Edges Lower; Nike Sales Miss Estimates
    Dec 22 AlloVir halts Phase 3 studies over efficacy, stock plunges 65%
    Dec 22 Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls
    Dec 22 AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
    Nov 16 AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
    See more ALVR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.1
    52 Week Low 0.6231
    Average Volume 457,894
    200-Day Moving Average 1.54
    50-Day Moving Average 0.76
    20-Day Moving Average 0.78
    10-Day Moving Average 0.80
    Average True Range 0.04
    RSI (14) 50.00
    ADX 21.04
    +DI 14.74
    -DI 12.11
    Chandelier Exit (Long, 3 ATRs) 0.72
    Chandelier Exit (Short, 3 ATRs) 0.82
    Upper Bollinger Bands 0.83
    Lower Bollinger Band 0.73
    Percent B (%b) 0.51
    BandWidth 12.38
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram -0.0001
    Fundamentals Value
    Market Cap 89.17 Million
    Num Shares 114 Million
    EPS -1.67
    Price-to-Earnings (P/E) Ratio -0.47
    Price-to-Sales 0.00
    Price-to-Book 0.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.83
    Resistance 3 (R3) 0.84 0.82 0.82
    Resistance 2 (R2) 0.82 0.81 0.82 0.82
    Resistance 1 (R1) 0.80 0.80 0.80 0.80 0.82
    Pivot Point 0.79 0.79 0.79 0.79 0.79
    Support 1 (S1) 0.77 0.78 0.76 0.77 0.75
    Support 2 (S2) 0.76 0.77 0.75 0.74
    Support 3 (S3) 0.74 0.76 0.74
    Support 4 (S4) 0.73